LEDERLE DISCONTINUING VIPROSTOL BALDNESS STUDIES, WILL GO COSMETIC
LEDERLE DISCONTINUING VIPROSTOL BALDNESS STUDIES, WILL GO COSMETIC route to a product for hair thinning, American Cyanamid noted in an April 19 press release reporting the firm's first quarter financial results. Through its Shulton Group, the company plans to introduce at the beginning of 1989 a new line of cosmetic products for men with thinning hair beginning in 1989. "The [new Shulton] line is based on experience gained from products included in a three-prong study on the treatment of male pattern baldness, and from research of consumer needs and desires and Shulton's assessment of the market potential," Cyanamid Chairman George Sella remarked. "The study included the vasodilator viprostol, a carrier lotion and a placebo, [and] the individual differences in the results were not sufficiently significant to warrant further effort on viprostol." In late 1986, Lederle enrolled over 1,000 male patients at 28 centers for the Phase III study of viprostol as a topical, prescription treatment for pattern baldness ("The Pink Sheet" Oct. 6, 1986, T&G-2). An earlier trial had tested the vasodilator in 150 patients at eight centers. At the time that Lederle expanded the clinical program, the company acknowledged the difficulty that lay ahead, noting that is was "too early" to determine whether the program would lead to "an efficacious product." After a review of the six-month data, which occurred in the first quarter of 1988, the company decided to discontinue viprostol studies "in view of the modest response rate in a limited market . . . and the cost of further studies."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: